Glucagon-like peptide-1 receptor agonists in orthopaedics

TL;DR

This paper explores how GLP-1 receptor agonists, used for blood sugar and weight control, may also benefit bone health and orthopedic recovery.

Contribution

It provides a summary of current evidence on GLP-1RA effects on bone metabolism and their role in orthopedics.

Findings

GLP-1RA drugs modulate osteoblast and osteoclast activity.

They influence inflammatory pathways and neuroprotective systems.

More research is needed on long-term safety and treatment comparisons.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery. There is growing amount of evidence of their ability to modulate the activity of osteoblasts and osteoclasts, affect inflammatory pathways, and interact with neuroprotective and psychological systems. Although the growing importance of GLP-1 receptor agonists in orthopaedics marks a major shift in how metabolic medicines affect musculoskeletal health, current knowledge is still basic and lacks information on long-term results, safety, and how well different treatments work compared to one another. This paper summarizes the existing evidence on the effects of GLP-1RA drugs on bone metabolism and healing, and discusses their role in current orthopaedics.

Figures